PCVX Forex News

Vaxcyte Says FDA OK's IND Application Of VAX-31 For Prevention Of Invasive Pneumococcal Disease

Vaccine maker Vaxcyte, Inc. (PCVX) announced Thursday that the U.S. Food and Drug Administration (FDA) has cleared the Company's adult Investigational New Drug (IND) application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).

RTTNews | 582 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.1348	GBPUSD	1.3497	AUDUSD	0.64619
USDJPY	143.376	USDCAD	1.38104	USDCHF	0.82655

Advertisement

PCVX Forex News

Vaxcyte Says FDA OK's IND Application Of VAX-31 For Prevention Of Invasive Pneumococcal Disease